P-glycoprotein expression is associated with fdg uptake and cell differentiation in patients with untreated lung cancer

Nuclear Medicine Communications

Volumn 25, Issue 1, 2004, Pages 19-27

  Higashi, K ^a   Ueda, Y ^a   Ikeda, R ^a   Kodama, Y ^a   Guo, J ^a   Matsunari, I ^a   Oguchi, M ^a   Tonami, H ^a   Katsuda, S ^a   Yamamoto, I ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cell differentiation; FDG PET; Lung cancer; Multidrug resistance; P glycoprotein

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GLYCOPROTEIN P; TRACER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MALE; MULTIDRUG RESISTANCE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; THORACOTOMY;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; AGED; AGED, 80 AND OVER; CELL DIVISION; DRUG RESISTANCE, MULTIPLE; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; TUMOR MARKERS, BIOLOGICAL;

EID: 10744230327     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200401000-00004     Document Type: Article

References (30)

1. Volm M, Mattern J. Detection of multiple mechanisms in untreated human lung cancer. Onkologie 1993; 16: 189-194.
2. 6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int J Cancer 1994; 59: 629-636.
3. Volm M. Multidrug resistance and its reversal. Anticancer Res 1998; 18: 2905-2918.
4. Scagliotti GV, Novello S, Selvaggi G. Multidrug resistance in non-small-cell lung cancer. Ann Oncol 1999; 10: 83-86.
5. Gottesman MM. How cancer cells evade chemotherapy. Cancer Res 1993; 53: 747-754.
6. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8: 67-113.
7. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistance human lung cancer cell line. Science 1992; 258: 1650-1654.
8. Bentley J, Bell SE, Quinn DM, Kellett GL, Warr JR. 2-deoxy-D-glucose toxicity and transport in human multidrug-resistant KB carcinoma cell lines. Oncol Res 1996; 8: 77-84.
9. Bentley J, Quinn DM, Pitman RS, Warr JR, Kellett GL. The human KB multi-drug-resistant cell line KB-Cl is hypersensitive to inhibitors of glycosylation. Cancer Lett 1997; 115: 221-227.
10. Lorke DE, Kruger M, Buchert R, et al. In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. J Nucl Med 2001; 42: 646-654.
11. Strauss LG, Koomaegi R, Dimitrakopoulou-Strauss A, et al. Dynamic positron emission tomography (PET) with F-18 deoxyglucose (FDG) in bone tumors: correlation of quantitative PET and gene expression. J Nucl Med 2001; 42: 33 (abstract).
12. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. J Nucl Med 1998; 39: 1302-1305.
13. Higashi T, Tamaki N, Torizuka, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39: 1727-1735.
14. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-269.
15. Brown RS, Leung JY, Paul LK, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 556-565.
16. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997; 80: 1046-1051.
17. Ferretti A, Chen LL, Di Vito M, et al. Pentose phosphate pathway alterations in multi-drug resistant leukemic T-cells: 31p NMR and enzymatic studies. Anticancer Res 1993; 13: 867-872.
18. Rochlitz CF, Lobeck H, Peter S, et al. Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype. Cancer 1992; 69: 2993-2998.
19. Kanamaru H, Kakehi Y, Yoshida O, et al. Mdr1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicine resistance by quinidine in tumor explants. J Natl Cancer Inst 1989; 81: 844-849.
20. Bosch S, Siavoshian S, Jacquot C, et al. Correlation between multidrug resistance and the degree of differentiation of non-small cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. Anticancer Res 1997; 17: 4595-4598.
21. Hendrikse NH, Franssen EJF, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999; 26: 283-293.
22. Sugawara I. Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta Pathol Jpn 1990; 40: 545-553.
23. Abe Y, Nakamura M, Ota E, et al. Expression of the multidrug resistance gene (MDR1) in non-small cell lung cancer. Jpn J Nucl Res 1994; 85: 536-541.
24. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar carcinoma. J Nucl Med 1998; 39: 1016-1020.
25. Dunnill MS, Gatter KC. Cellular heterogeneity in lung cancer. Histopathology 1986; 10: 461-475.
26. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002; 43: 500-509.
27. 99mTc-MIBI with the expression of P-glycoprotein in lung cancer. J Nucl Med 1998; 39: 228-234.
28. 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med 2001; 42: 1476-1483.
29. 14C]-colchicine biodistribution with whole body quantitative autoradiography in colchicine-sensitive and -resistant xenografts. J Nucl Med 1996; 37: 312-314.
30. 11C-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med 1996; 37: 1571-1575.